Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Up 181.1% in May


Altamira Therapeutics Ltd. (NASDAQ: CYTOGet a rating) benefited from a significant increase in short-term interest during the month of May. As of May 31, there were short interests totaling 339,800 shares, an increase of 181.1% from the May 15 total of 120,900 shares. Based on an average trading volume of 1,290,000 shares, the short interest ratio is currently 0.3 days. Currently, 2.4% of the stock’s shares are sold short.

Institutional investors have recently increased or reduced their stake in the company. Morgan Stanley bought a new stake in shares of Altamira Therapeutics during the third quarter worth about $31,000. Two Sigma Investments LP bought a new stake in shares of Altamira Therapeutics during the third quarter for a value of approximately $32,000. Geode Capital Management LLC purchased a new stake in shares of Altamira Therapeutics during the third quarter at a value of approximately $37,000. BlackRock Inc. bought a new stake in shares of Altamira Therapeutics during the third quarter worth approximately $65,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Altamira Therapeutics during the third quarter at a value of approximately $116,000. Hedge funds and other institutional investors own 3.80% of the company’s shares.

Altamira Therapeutics Stock opened at $0.57 on Friday. Altamira Therapeutics has a 12-month low of $0.56 and a 12-month high of $4.13. The company’s 50-day moving average price is $0.87 and its two-hundred-day moving average price is $1.15.

About Altamira Therapeutics (Get a rating)

Altamira Therapeutics Ltd. engages in the development of therapeutic products that address a variety of unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA-based therapies for extrahepatic therapeutic targets, including the OligoPhore and SemaPhore platforms which are at the preclinical stage for the delivery of oligonucleotides and mRNA; AM-125 which is in a phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in a phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi which is in phase III clinical development for the treatment of acute inner ear deafness.

Featured Articles



Get news and reviews for Altamira Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Altamira Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.